Subscribe
fees-gavel-istock-542099686-tzahiv--1
tzahiV / iStockphoto.com
25 September 2017Americas

Gilead escapes enhanced damages in $2.5bn Idenix verdict

Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.

More on this story

Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC